For millions of older Americans, medications such as Ozempic and Wegovy have transformed the conversation around weight management and chronic disease. These drugs, known as GLP-1s, have shown remarkable effectiveness in helping many people lose significant weight, improve blood sugar control, and reduce the risk of certain cardiovascular events.

Until recently, however, Medicare coverage for these medications has been limited, leaving many beneficiaries to pay hundreds—or even thousands—of dollars out of pocket each month.

A Medicare demonstration program that began on July 1, 2026, aims to change that by expanding access to anti-obesity medications at a steep discount for eligible beneficiaries: just $50 a month.

While the initiative represents a significant policy shift, it also raises important questions about who qualifies, what participants can expect, and what may happen once the demonstration period ends.

Who Is Eligible?

Generally, participants in the demonstration project must be clinically obese, typically defined as a body mass index (BMI) of 35 or higher, or be overweight with other weight-related health conditions such as hypertension, heart disease, or obstructive sleep apnea.

About 3 million Medicare beneficiaries are expected to qualify, even though fewer are likely to participate.

Enrollment also requires that beneficiaries be enrolled in Medicare Part D (drug plan). They must also participate in a comprehensive weight-management program, working with healthcare professionals on nutrition, physical activity, and behavioral counseling.

To obtain coverage, patients must first be evaluated by their physician or another qualified healthcare provider to determine if they meet the eligibility requirements. Because eligibility also depends on your Medicare Part D coverage, it’s important to understand how your prescription drug plan fits into your overall Medicare strategy.

Changes like this are a good reminder that Medicare isn’t something you choose once and forget. Coverage options, prescription drug benefits, and costs can change from year to year.

With Medicare’s annual Open Enrollment period coming up October 15 through December 7, this is a good time to start thinking about your coverage and whether it continues to meet your healthcare needs and fit within your overall retirement plan.

Potential Benefits

The excitement surrounding GLP-1 medications is well deserved. Clinical trials have shown that many patients lose 15% to 20% or more of their body weight, results that were previously achievable primarily through bariatric surgery.

The benefits extend well beyond the number on the scale. Weight loss can improve blood pressure, lower cholesterol, reduce the risk of developing type 2 diabetes, ease joint pain, and enhance overall quality of life. Some GLP-1 medications have also demonstrated significant reductions in heart attacks, strokes, and cardiovascular death among certain high-risk patients.

For older adults, even modest weight loss can improve independence by making everyday activities easier and reducing stress on weight-bearing joints. Improved metabolic health may also decrease the need for additional medications over time.

Jay Butler, a 73-year-old retired entrepreneur in Philadelphia, just qualified and took his first shot of Zepbound. He hopes to lose 25 to 30 pounds “at a minimum.”

“I’ve always been thick, and I don’t think I’ll ever be thin,” said Butler. He’s had five surgeries on his knees and back over the past five years. “Hopefully, this will be good for my knees and back and maybe get me off my blood pressure meds.”

Understanding the Risks

Despite their promise, GLP-1 medications are not appropriate for everyone. The most common side effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These symptoms often improve as the body adjusts to the medication, but some patients discontinue treatment because of persistent gastrointestinal problems.

Another important consideration is that the medications are intended for long-term use. Research has shown that many people regain much of the lost weight after stopping treatment. This means beneficiaries considering therapy should view it as an ongoing component of chronic disease management rather than a short-term solution.

In addition, significant weight loss can lead to a loss in muscle mass and bone density, which are already problem areas for many older adults.

Looking Beyond the Demonstration

Perhaps the biggest question is what happens after the demonstration program expires at the end of 2027.

Demonstration projects allow Medicare to evaluate whether new approaches improve health outcomes while controlling overall healthcare costs. During the program, federal officials will closely monitor weight loss, health outcomes, medication adherence, healthcare utilization, and total spending.

If the data show that broader GLP-1 coverage improves health while reducing expensive complications such as heart attacks, diabetes, or hospitalizations, Medicare could make expanded coverage permanent through future policy or legislative changes.

On the other hand, if the demonstration finds that the costs outweigh the savings or that health benefits are more modest than expected in the Medicare population, coverage could be scaled back or discontinued once the project concludes.

Even if broad coverage is not permanently adopted, it may identify which patients benefit most, or lead to more targeted coverage for individuals at highest medical risk.

What’s Next for Medicare and GLP-1 Coverage?

The Medicare GLP-1 demonstration represents an important recognition that obesity is a chronic medical condition rather than simply a matter of willpower.

But participants should understand that these medications, though now affordable, are not without risks and are most effective when combined with sustained lifestyle changes and regular medical supervision.

As Medicare continues evaluating expanded GLP-1 coverage, beneficiaries may see additional changes in the years ahead. Whether you’re considering these medications, comparing Medicare plans during Open Enrollment, or simply planning for healthcare costs in retirement, understanding how your healthcare choices and costs fit into your overall financial picture is important.

If you have questions about how healthcare costs may affect your overall financial plan, give us a call. We’re always happy to help you understand the bigger picture and determine the right next steps.